Bristol Myers Squibb will pay $475 million to license an experimental cytokine drug from Dragonfly Therapeutics. The therapy, called DF6002, is an IL-12 immunoglobulin Fc fusion protein. IL-12 helps ...
The dragon is flying high today as Merck hits go on a second immunotherapy candidate from its $700 million pact with Dragonfly Therapeutics. The Big Pharma's buy-in comes just a month after Bristol ...
CD33 is known to be highly expressed in myeloid cells and a good therapeutic target for treating acute myeloid leukemia (AML). In the search for more potent compounds, researchers from Dragonfly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results